Replies to post #6691 on Revance Therapeutics Inc (RVNC)

[mrwilson31]

Nice work. Good find.

First line treatment means that toxins are the go to for that specific indication. It does not mean preferred status or formulary.
What they are saying is that they have 2/3 of the countries coverage handled. Insurance plans are now giving them the thumbs for utilization in the CD space.

That statement is like saying - We now have the right to play in 2/3 of the sandboxes out there.

[mrwilson31]

I’m going to eat crow here. I misread that statement. My apologies. I was wrong.

[vinmantoo]

Dew, thanks for that information. It is good to correct some errors, I will call them honest mistakes to be kind, that mrwilson has posted. This part from the RVNC CC is worth repeating.

As a reminder, with a new toxin, physicians tend to start patients at the lower end of the dosing range before titrating them up over subsequent treatment cycles. In order to find the optimal balance between symptom control and safety, despite being early in the dose optimization journey. When surveyed 94% of previous physicians who have been in the program since its inception indicated that they perceived diversified to last longer than other toxins based on their first treatment cycle.

I assume there was a transcribing error as it should have read

When surveyed 94% of previous physicians who have been in the program since its inception indicated that they perceived Daxxify to last longer than other toxins based on their first treatment cycle.

[mrwilson31]

“almost two thirds of that coverage is going to be first-line therapy.”

First line therapy does not mean preferred!

It means that the specific class of medications is first line therapy.

Botulinum toxins have been a long-established first line therapy.

So, 17% of the plans do not think toxins are first line therapy. Which is true.

[mrwilson31]

Here is just one quick example.

Medicare Part B for Aetna Medicare Advantage July of 2023.

I know this is just one of a thousand plans.

Botox is the non-preferred toxin.
Xeomin and Dysport are the preferred toxins over Botox.

https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/health-care-professionals/aetna-medicare-advantage-with-prescription-drug-coverage-(mapd)-2023-part-b-preferred-drug-list.pdf

In North Carolina the Blues prefer Dysport and Xeomin.

You better hope that Revance has a really good team working on getting preferred status. First line therapy was a statement utilized to wow investors.

So, the pie is even smaller than originally thought.
There is more potential in Spasticity.

[DewDiligence]

RVNC formally launches Daxxify for cervical dystonia:

https://investors.revance.com/investors/Press-Releases/news-details/2024/Revance-Expands-into-the-U.S.-Therapeutics-Market-with-the-Launch-of-DAXXIFY-for-the-Treatment-of-Cervical-Dystonia/default.asp